Thomas X, Vila L, Campos L, Sabido O, Archimbaud E
Service d'Hématologie, Hôpital Edouard Herriot, UFR Alexis Carrel, Lyon, France.
Leuk Lymphoma. 1995 Oct;19(3-4):295-300. doi: 10.3109/10428199509107901.
Expression of CD56 was analyzed by indirect immunofluorescence method on bone marrow samples from 94 newly diagnosed patients with acute leukemia (AL), including 59 acute myelogenous leukemias (AML) and 35 acute lymphoblastic leukemias (ALL). CD56 was expressed on 17 +/- 18% (range: 0-72%) of AML cells and 24 +/- 24% (range: 0-98%) of ALL cells, without significant differences between FAB subtypes in AML, nor immunologic subtypes in ALL. Expression of CD56 was not associated with any clinical or biological characteristic at diagnosis, nor with prognosis in AML or ALL. We do not confirm previously described relationships between CD56 expression and initial characteristics and evolution of acute leukemia.
采用间接免疫荧光法对94例新诊断的急性白血病（AL）患者的骨髓样本进行CD56表达分析，其中包括59例急性髓系白血病（AML）和35例急性淋巴细胞白血病（ALL）。CD56在17±18%（范围：0 - 72%）的AML细胞和24±24%（范围：0 - 98%）的ALL细胞中表达，在AML的FAB亚型之间或ALL的免疫亚型之间无显著差异。CD56的表达与诊断时的任何临床或生物学特征均无关，也与AML或ALL的预后无关。我们未证实先前描述的CD56表达与急性白血病的初始特征及病程之间的关系。
